Paclitaxel-Based Chemoradiotherapy in Localized Gastric Carcinoma: Degree of Pathologic Response and Not Clinical Parameters Dictated Patient Outcome
- 20 February 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (6) , 1237-1244
- https://doi.org/10.1200/jco.2005.01.305
Abstract
Purpose Preoperative chemoradiotherapy may increase the R0 (curative) resection rate, overall survival (OS) duration, and disease-free survival (DFS) duration. We evaluated paclitaxel-based induction chemotherapy and chemoradiotherapy in patients with localized gastric or gastroesophageal adenocarcinoma to determine its feasibility, impact on the R0 resection rate, type of pathologic response, OS, and DFS. Patients and Methods Patients with operable, localized gastric, or gastroesophageal adenocarcinoma were eligible. Staging included endoscopic ultrasonography (EUS) and laparoscopy. Patients received two 28-day cycles of induction chemotherapy of fluorouracil, paclitaxel, and cisplatin followed by 45 Gy of radiation and concurrent fluorouracil plus paclitaxel. The cancer was restaged and surgery was attempted. Postsurgery pathologic findings and R0 resection were correlated with OS and DFS. Results Forty-one patients were enrolled. Most carcinomas were proximal (83%) and pretreatment stage EUST3 (85%). Forty patients (98%) underwent surgery, and 78% had an R0 resection. We observed a pathologic complete response (pathCR) rate of 20% and a pathologic partial response (pathPR) rate of 15% (< 10% residual cancer cells in the resected specimen). No pretreatment parameter (sex, cancer location, baseline T stage, or baseline N stage) predicted the type of postsurgery pathologic response, OS, or DFS. However, pathCR (P = .02), pathCR + pathPR (P = .006), R0 resection (P < .001), and postsurgery T and N stages (P = .01 and P < .001, respectively) were associated with OS. Same parameters were significantly correlated with DFS. Toxicity was manageable. Conclusion The type of pathologic response but not pretreatment parameters was associated with OS and DFS. Efforts to increase the rate of pathologic response and better systemic cancer control are warranted.Keywords
This publication has 10 references indexed in Scilit:
- Multi-Institutional Trial of Preoperative Chemoradiotherapy in Patients With Potentially Resectable Gastric CarcinomaJournal of Clinical Oncology, 2004
- Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal JunctionNew England Journal of Medicine, 2001
- Paclitaxel and concurrent radiation for gastric cancerInternational Journal of Radiation Oncology*Biology*Physics, 2000
- The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomyCancer, 2000
- Extended Lymph-Node Dissection for Gastric CancerNew England Journal of Medicine, 1999
- Laparoscopy in 533 patients with abdominal malignancySurgery, 1999
- Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.Journal of Clinical Oncology, 1998
- Laparoscopic staging for gastric cancerSurgery, 1996
- Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the EsophagusJNCI Journal of the National Cancer Institute, 1994
- Cancer of the StomachAnnals of Surgery, 1993